Versor Investments LP Acquires 4,313 Shares of Masimo Co. (NASDAQ:MASI)

Versor Investments LP raised its stake in shares of Masimo Co. (NASDAQ:MASI) by 81.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,591 shares of the medical equipment provider’s stock after purchasing an additional 4,313 shares during the quarter. Versor Investments LP’s holdings in Masimo were worth $1,279,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. NBC Securities Inc. grew its position in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares during the period. GAMMA Investing LLC increased its position in shares of Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the last quarter. HHM Wealth Advisors LLC boosted its position in Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares in the last quarter. Finally, Lazard Asset Management LLC grew its stake in Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 573 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MASI has been the topic of several recent analyst reports. Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price on the stock in a report on Wednesday, November 6th. BTIG Research boosted their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company raised their target price on Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Piper Sandler increased their price objective on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $163.67.

Masimo Trading Down 0.5 %

MASI opened at $161.63 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.15 and a current ratio of 2.01. Masimo Co. has a twelve month low of $86.94 and a twelve month high of $173.90. The firm’s fifty day moving average is $133.52 and its two-hundred day moving average is $125.93. The firm has a market cap of $8.65 billion, a PE ratio of 111.47 and a beta of 0.97.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same period in the prior year, the company earned $0.63 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Equities research analysts anticipate that Masimo Co. will post 4.04 EPS for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.